Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Ann Hematol. 2023 Jan;102(1):133-140. doi: 10.1007/s00277-022-05052-x. Epub 2022 Nov 19.


Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m2 on day 1, and bendamustine 90 mg/m2 on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.

Keywords: Bendamustine; Diffuse large B-cell lymphoma; Polatuzumab vedotin; Refractory; Relapsed; Rituximab.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bendamustine Hydrochloride / adverse effects
  • Humans
  • Immunoconjugates* / therapeutic use
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Lymphoma, Non-Hodgkin* / drug therapy
  • Rituximab / adverse effects
  • Turkey / epidemiology


  • Rituximab
  • polatuzumab vedotin
  • Bendamustine Hydrochloride
  • Immunoconjugates